TY  - JOUR
A1  - Fortmann, Ingmar
A1  - Dammann, Marie-Theres
A1  - Humberg, Alexander
A1  - Siller, Bastian
A1  - Stichtenoth, Guido
A1  - Engels, Geraldine
A1  - Marißen, Janina
A1  - Faust, Kirstin
A1  - Hanke, Kathrin
A1  - Goedicke-Fritz, Sybelle
A1  - Derouet, Christoph
A1  - Meyer, Sascha
A1  - Stutz, Regine
A1  - Kaiser, Elisabeth
A1  - Herting, Egbert
A1  - Göpel, Wolfgang
A1  - Härtel, Christoph
A1  - Zemlin, Michael
T1  - Five year follow up of extremely low gestational age infants after timely or delayed administration of routine vaccinations
JF  - Vaccines
N2  - This study is aimed at detecting the rate of untimely immunization in a large cohort of extremely low gestational age neonates (ELGANs) of the German Neonatal Network (GNN) and at addressing risk factors for delayed vaccination and associated long-term consequences. We performed an observational study of the GNN between 1st January 2010 and 31st December 2019. The immunization status for the hexavalent and pneumococcal immunization was evaluated in n = 8401 preterm infants <29 weeks of gestation. Univariate analysis and logistic/linear regression models were used to identify risk factors for vaccination delay and outcomes at a 5-year follow-up. In our cohort n = 824 (9.8%) ELGANs did not receive a timely first immunization with the hexavalent and pneumococcal vaccine. Risk factors for delayed vaccination were SGA status (18.1% vs. 13.5%; OR 1.3; 95% CI: 1.1–1.7), impaired growth and surrogates for complicated clinical courses (i.e., need for inotropes, necrotizing enterocolitis). At 5 years of age, timely immunized children had a lower risk of bronchitis (episodes within last year: 27.3% vs. 37.7%; OR 0.60, 95% CI: 0.42–0.86) but spirometry measures were unaffected. In conclusion, a significant proportion of ELGANs are untimely immunized, specifically those with increased vulnerability, even though they might particularly benefit from the immune-promoting effects of a timely vaccination.
KW  - immunization
KW  - prematurity
KW  - trained immunity
KW  - long-term outcome
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239592
SN  - 2076-393X
VL  - 9
IS  - 5
ER  - 
TY  - JOUR
A1  - Lüke, Florian
A1  - Haller, Florian
A1  - Utpatel, Kirsten
A1  - Krebs, Markus
A1  - Meidenbauer, Norbert
A1  - Scheiter, Alexander
A1  - Spoerl, Silvia
A1  - Heudobler, Daniel
A1  - Sparrer, Daniela
A1  - Kaiser, Ulrich
A1  - Keil, Felix
A1  - Schubart, Christoph
A1  - Tögel, Lars
A1  - Einhell, Sabine
A1  - Dietmaier, Wolfgang
A1  - Huss, Ralf
A1  - Dintner, Sebastian
A1  - Sommer, Sebastian
A1  - Jordan, Frank
A1  - Goebeler, Maria-Elisabeth
A1  - Metz, Michaela
A1  - Haake, Diana
A1  - Scheytt, Mithun
A1  - Gerhard-Hartmann, Elena
A1  - Maurus, Katja
A1  - Brändlein, Stephanie
A1  - Rosenwald, Andreas
A1  - Hartmann, Arndt
A1  - Märkl, Bruno
A1  - Einsele, Hermann
A1  - Mackensen, Andreas
A1  - Herr, Wolfgang
A1  - Kunzmann, Volker
A1  - Bargou, Ralf
A1  - Beckmann, Matthias W.
A1  - Pukrop, Tobias
A1  - Trepel, Martin
A1  - Evert, Matthias
A1  - Claus, Rainer
A1  - Kerscher, Alexander
T1  - Identification of disparities in personalized cancer care — a joint approach of the German WERA consortium
JF  - Cancers
N2  - (1) Background: molecular tumor boards (MTBs) are crucial instruments for discussing and allocating targeted therapies to suitable cancer patients based on genetic findings. Currently, limited evidence is available regarding the regional impact and the outreach component of MTBs; (2) Methods: we analyzed MTB patient data from four neighboring Bavarian tertiary care oncology centers in Würzburg, Erlangen, Regensburg, and Augsburg, together constituting the WERA Alliance. Absolute patient numbers and regional distribution across the WERA-wide catchment area were weighted with local population densities; (3) Results: the highest MTB patient numbers were found close to the four cancer centers. However, peaks in absolute patient numbers were also detected in more distant and rural areas. Moreover, weighting absolute numbers with local population density allowed for identifying so-called white spots—regions within our catchment that were relatively underrepresented in WERA MTBs; (4) Conclusions: investigating patient data from four neighboring cancer centers, we comprehensively assessed the regional impact of our MTBs. The results confirmed the success of existing collaborative structures with our regional partners. Additionally, our results help identifying potential white spots in providing precision oncology and help establishing a joint WERA-wide outreach strategy.
KW  - precision oncology
KW  - MTB
KW  - patient access
KW  - cancer care
KW  - outreach
KW  - real world data
KW  - outcomes research
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-290311
SN  - 2072-6694
VL  - 14
IS  - 20
ER  -